moderate - Equipment sales (40-45% of revenue) are cyclical, tied to hospital capital budgets which correlate with GDP growth, patient volumes, and healthcare system profitability. U.S. hospital systems defer imaging equipment purchases during recessions when patient volumes decline and reimbursement pressures intensify. However, 60% recurring revenue from service contracts, consumables, and pharmaceuticals provides stability. International exposure (50% of revenue) creates sensitivity to emerging market growth, particularly China where healthcare infrastructure investment drives 15-20% of sales.

Rising rates create moderate headwind through two channels: (1) Hospital customers face higher financing costs for capital equipment purchases, potentially delaying $1-5M imaging system orders and extending sales cycles; (2) GEHC's $3.5B debt (0.96x D/E) increases interest expense, though most debt is fixed-rate from spin capitalization. Valuation multiple compression occurs as investors rotate from growth-oriented med-tech (trading at 20-25x P/E) toward higher-yielding alternatives. However, healthcare equipment demand is less rate-sensitive than discretionary sectors given clinical necessity and regulatory-driven technology upgrades.

value - Stock trades at 1.9x P/S and 11.8x EV/EBITDA, below med-tech peers (15-20x EBITDA), attracting investors focused on post-spin margin expansion story, FCF yield of 4.1%, and potential re-rating as standalone pure-play. Recent -14.1% one-year return creates entry point for investors betting on 15%+ operating margin achievement and 6-8% organic growth acceleration. Limited dividend (company prioritizing debt paydown) reduces income investor appeal.